Trial record 9 of 105 for:    "Measles"

Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors

This study is not yet open for participant recruitment.
Verified May 2012 by Queen Saovabha Memorial Institute
Sponsor:
Information provided by (Responsible Party):
Jaruboot Angsanakul, Queen Saovabha Memorial Institute
ClinicalTrials.gov Identifier:
NCT01602094
First received: May 16, 2012
Last updated: May 17, 2012
Last verified: May 2012
  Purpose

Prevalence of participants who have protective immunity to measles virus is less than ninety percent.

Predictor of adequate measles antibody levels include the following :

  • History of measles infection
  • History of complete measles primary immunization( 2 doses with at least 1 month interval after age of 9 months)
  • History of measles exposure

Predictor of inadequate measles antibody levels include the following :

  • Born outside Thailand
  • History of staying outside Thailand for long time in childhood
  • Living in the rural area for a long period in childhood
  • Fail to participate school system on time

Condition
Measles

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors

Resource links provided by NLM:


Further study details as provided by Queen Saovabha Memorial Institute:

Biospecimen Retention:   Samples Without DNA

Each participant will be taken blood sample approximately 8 ml. The blood sample will be centrifuged and kept as serum. The serum will be kept under - 20 degree Celsius. Then, all serum will be tested by ELISA.


Estimated Enrollment: 550
Study Start Date: July 2012
Estimated Study Completion Date: March 2013
Estimated Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
Adequate antimeales antibody levels
ELISA test OD > 0.1
Inadequate measles antibody levels
ELISA test OD < 0.1

  Eligibility

Ages Eligible for Study:   18 Years to 30 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Health Thai participant age 18-30 years old.

Criteria

Inclusion Criteria:

  • Age 18-30 years old

Exclusion Criteria:

  • Last measles vaccination less than 10 years of age
  • Immunocompromised host including congenital immune defect, splenectomy or splenic dysfunction, history of suspect HIV exposure, taking immunosuppressant
  • Receiving blood or blood product within 3 months
  • Receiving others vaccinations or immunoglobulins or any medication that possibly decrease immune response
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01602094

Contacts
Contact: Jaruboot Angsanakul, M.D. 662-252-0161-4 ext 132 jaruboot@yahoo.com

Locations
Thailand
Queen Saovabha Memorial Institute Not yet recruiting
Bangkok, Thailand, 10330
Contact: Maneerat Benjavongkulchai, R.N.    662-252-0161-4 ext 124    neowmanee@yahoo.com   
Principal Investigator: Jaruboot Angsanakul, M.D.         
Sub-Investigator: Maneerat Benjavongkulchai, R.N.         
Sponsors and Collaborators
Queen Saovabha Memorial Institute
Investigators
Principal Investigator: Jaruboot Angsanakul, M.D. Queen Saovabha Memorial Institute
  More Information

Additional Information:
No publications provided

Responsible Party: Jaruboot Angsanakul, Queen Saovabha Memorial Institute
ClinicalTrials.gov Identifier: NCT01602094     History of Changes
Other Study ID Numbers: TAI5501
Study First Received: May 16, 2012
Last Updated: May 17, 2012
Health Authority: Thailand: Ministry of Public Health

Keywords provided by Queen Saovabha Memorial Institute:
measles
antibody
prevalence
predictors
Donor of National Blood Centre, The Thai Red Cross Society who age 18-30 years old
Measles antibody levels
Predictors of adequate measles antibody levels and inadequate measles antibody levels

Additional relevant MeSH terms:
Measles
Morbillivirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections
Virus Diseases
Antibodies
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 17, 2014